Drug Profile
Amrubicin - Sumitomo Pharma
Alternative Names: Amrubicin hydrochloride; Calsed; CNF3140; SM-5887Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Celgene Corporation; Icahn School of Medicine at Mount Sinai; SCRI Development Innovations; Stanford University; Sumitomo Pharma
- Class Amines; Anthracyclines; Antineoplastics; Cytostatic antibiotics; Naphthacenes; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Small cell lung cancer
- Discontinued Bladder cancer; Breast cancer; Malignant thymoma; Multiple myeloma
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 08 Apr 2021 Discontinued - Phase-I/II for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV)
- 08 Apr 2021 Discontinued - Phase-I/II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV)